Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catharine Clark

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Medical Physics|October 28, 2024
Which failures do patient-specific quality assurance systems need to catch?Jennifer O'Daniel, Victor Hernandez, Catharine Clark, et al.
International Journal of Radiation Oncology, Biology, Physics|January 18, 2011
Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancersAisha B Miah, Shreerang A Bhide, M Teresa Guerrero-Urbano, et al.
The Lancet. Oncology|December 16, 2011
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trialDavid Dearnaley, Isabel Syndikus, Georges Sumo, et al.
The Lancet. Oncology|January 18, 2011
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trialChristopher M Nutting, James P Morden, Kevin J Harrington, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Medical Physics|October 28, 2024
Which failures do patient-specific quality assurance systems need to catch?Jennifer O'Daniel, Victor Hernandez, Catharine Clark, et al.
International Journal of Radiation Oncology, Biology, Physics|January 18, 2011
Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancersAisha B Miah, Shreerang A Bhide, M Teresa Guerrero-Urbano, et al.
The Lancet. Oncology|December 16, 2011
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trialDavid Dearnaley, Isabel Syndikus, Georges Sumo, et al.
The Lancet. Oncology|January 18, 2011
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trialChristopher M Nutting, James P Morden, Kevin J Harrington, et al.
Pageof 1